We updated the design of this site on September 25th. Learn more.

The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified October 2013 by Meir Medical Center.
Recruitment status was: Recruiting

Sponsor:

ClinicalTrials.gov Identifier:

NCT01809574

First Posted: March 12, 2013

Last Update Posted: April 9, 2015

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

Meir Medical Center

Purpose

We hypothesized that the multi-disciplinary assessment of interstitial lung disease patients would lead to a more accurate diagnosis and consequently alterations in treatment regimens that may lead to improved outcomes.

Condition
Interstitial Lung Disease Idiopathic Pulmonary Fibrosis Connective Tissue Disease


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

Resource links provided by NLM:

Genetics Home Reference related topics: idiopathic pulmonary fibrosis pulmonary alveolar microlithiasis

MedlinePlus related topics: Interstitial Lung Diseases Lung Diseases Pulmonary Fibrosis

Genetic and Rare Diseases Information Center resources: Idiopathic Pulmonary Fibrosis

U.S. FDA Resources

Further study details as provided by Meir Medical Center:

Primary Outcome Measures:

The number of patients with collagen related pulmonary fibrosis that are diagnosed by Rheumatologists compared to Pulmonologists. [ Time Frame: two years ]


Estimated Enrollment:	60
Study Start Date:	May 2013
Estimated Study Completion Date:	March 2016
Estimated Primary Completion Date:	March 2016 (Final data collection date for primary outcome measure)

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

60 patients that will refer to the pulmonary outpatient or inpatients department for evaluation due to ILD will be included

Criteria

Inclusion Criteria:

Age above 18 years old
ILD according to ATS/ERS guidelines
Signed inform consent

Exclusion Criteria:

Previous lung surgery
Other significant systemic disease

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01809574

Contacts


Contact: David Shitrit, Dr.	097471556	davids3@clalit.org.il

Locations


Israel
Meir Medical Center	Recruiting
Kfar Saba, Israel, 972
Contact: David Shitrit, Dr 09-7471556 davids3@clalit.org.il

Sponsors and Collaborators

Meir Medical Center

Investigators


Principal Investigator:	David Shitrit, Dr	Head of Pulmonary departmant, Meir Medical Center.

More Information


Responsible Party:	Meir Medical Center
ClinicalTrials.gov Identifier:	NCT01809574 History of Changes
Other Study ID Numbers:	225-12-MMC
First Submitted:	March 10, 2013
First Posted:	March 12, 2013
Last Update Posted:	April 9, 2015
Last Verified:	October 2013

Keywords provided by Meir Medical Center:


Interstitial lung disease Idiopathic pulmonary fibrosis Connective tissue disease

Additional relevant MeSH terms:


Fibrosis Lung Diseases Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Idiopathic Interstitial Pneumonias	Lung Diseases, Interstitial Connective Tissue Diseases Pathologic Processes Respiratory Tract Diseases

To Top